burosumab

01/01/2021 - "The reliability, validity, and sensitivity to change of the RGI-C were evaluated using data from two studies in pediatric XLH (113 children aged 1-12 years) in which burosumab treatment significantly improved rickets severity. "
01/01/2020 - "Prolonged treatment with burosumab showed a favorable safety profile, improved healing of rickets in children, and fractures and pseudofractures in adults. "
11/01/2022 - "Rickets severity scores and height z-scores also improved with burosumab. "
01/01/2021 - "Human MAB for FGF23, burosumab, has been shown to improve biochemical abnormalities, roentgenological signs of rickets, growth, fracture healing and impaired mineralization in patients with XLH. "
01/01/2022 - "Key suggestions made by our group were initiation of burosumab treatment in children as early as possible, from the age of 1 year, particularly in those with profound rickets, and a need for clinical studies on continuation of burosumab throughout adolescence and into adulthood."

08/27/2021 - "Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia."
12/17/2022 - "Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia."
10/01/2022 - "Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study."
05/01/2022 - "Safety and Efficacy of Burosumab in Pediatric Patients With X-Linked Hypophosphatemia: A Phase 3/4 Open-Label Trial."
01/01/2018 - "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis."

01/01/2020 - "Burosumab was initiated resulting in improvement in pain symptoms and mobility. "
01/01/2023 - "In September 2019, she was started on burosumab, initially at the dose of 0.3 mg/kg/month, progressively increased to the current 0.8 mg/kg/month, with great improvement of pain, physical performance, and normalization of SP levels. "
11/10/2022 - "Our patient was initiated on burosumab, which led to healing of his fractures and profound symptomatic improvement of his pain. "
10/01/2022 - "For the key secondary endpoints (WOMAC Stiffness and Physical Function; BPI-SF Worst Pain) individual subgroup categories showed improvements with burosumab relative to placebo. "
01/01/2022 - "Burosumab was beneficial on pain and disability scores and on bone remodeling markers. "

01/01/2018 - "Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia."
01/01/2023 - "The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome."
01/01/2022 - "A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome."
12/01/2021 - "Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report."
11/19/2021 - "Burosumab, a human monoclonal anti-FGF23 antibody, was recently post-marketed in Japan against for FGF23-related hypophosphatemia. "

01/01/2022 - "The concomitant decrease of highly mineralized matrix, persistence of lowly mineralized matrix, and increase in mineralized bone volume after burosumab suggest a boost in mineralization of preexisting unmineralized or very lowly mineralized matrix, providing a potential explanation for previously observed improved osteomalacia. "
12/01/2019 - "UX023-CL304 is an ongoing, open-label, single-arm, phase 3 study investigating the efficacy of subcutaneous burosumab, 1.0 mg/kg administered every 4 weeks, in improving osteomalacia in adults with XLH who have not been treated for at least 2 years before enrollment. "
01/01/2022 - "Burosumab for 48 weeks improved histological lesions of osteomalacia in a single-arm longitudinal study analyzing paired bone biopsies. "
01/01/2022 - "UX023-CL304 was an open-label, phase 3 study investigating the effects of burosumab on osteomalacia in adults with XLH, who remained untreated at least 2 years prior enrollment. "
01/01/2023 - "Our case shows efficacy and safety of burosumab treatment administered every 2 weeks in a tumour-induced osteomalacia (TIO) patient. "